Learn about DNA delivery and neurodegenerative disease modeling
We invite you to join our partners StressMarq's and Genscript's upcoming scientific webinars.
Fibrillar and oligomeric constructs of neurodegenerative disease associated peptides and their utility in disease modelling
Spreading of neurodegenerative disease associated peptides (NDAPs; e.g. tau and alpha-synuclein) within the human brain is one of the earliest pathological processes occurring in Alzheimer’s and Parkinson’s diseases. The study of these diseases necessitates the use of viable models that are representative of the disease in question. In order to create them, numerous tools are required that can induce the neuropathological processes in vitro and in vivo. For instance, transgenic animals over-expressing tau or alpha-synuclein endogenously, or animals expressing tau or alpha-synuclein mutants that aggregate more rapidly, are commonly used. An alternative approach is to introduce pre-formed fibrils of NDAPs into cells to induce pathology.
In this presentation, StressMarq will provide an overview of tools available for neurodegenerative research including different forms of NDAPs. They will demonstrate that certain fibrils and filaments can initiate protein aggregation, inducing disease pathology in vitro and in vivo. In addition, the presentation will cover important considerations for the handling of pre-formed fibrils to maintain activity such as the effects of sonication. Furthermore, examples of in vitro modelling of neuropathologies in neuronal circuits, using a proprietary high capacity microfluidics platform, will be shown.
Speaker: Ariel Louwrier, PhD, President & CEO of StressMarq Biosciences Inc.
Date: April 9 at 5 PM CEST / 11 AM EDT / 8 AM PDT
In vivo delivery of Cas9 ribonucleoprotein and donor DNA with gold nanoparticles
Cas9 based therapeutics have the potential to revolutionize the treatment of genetic diseases. However, safe and effective methods for delivering Cas9 protein, gRNA and donor DNA need to be developed before the therapeutic potential of CRISPR based therapeutics can be realized. In this presentation, Dr. Niren Murthy will describe a non-viral Cas9 delivery vehicle, termed CRISPR-Gold, which can induce homology directed DNA repair (HDR) in vivo by directly delivering Cas9 protein, gRNA, and donor DNA.
From this webinar, you will learn the following:
- Non-viral delivery of the Cas9 protein possible in vivo
- Gene editing after a local injection can have therapeutic effects
- New strategies for reversibly modifying proteins.
Speaker: Dr. Niren Murthy, Department of Bioengineering at the University of California at Berkeley.
Date: April 7, 2020, 1PM EST/ 10AM PST
Find a selection of recorded webinars and videos in our scientific content section.